Activation of NRF2 by cysteine electrophiles that inhibit KEAP1 has been extensively studied as a therapeutic approach in diverse disease contexts including NAFLD, where oxidative stress and inflammation drive disease pathologies (30). The gene discussed is KEAP1; the disease is metabolic dysfunction-associated steatotic liver disease.